Previous 10 | Next 10 |
2024-03-13 15:35:28 ET A California-based %Biotech company saw its shares soar on Wednesday, a day following the company’s Q4 earnings announcement. With analysts expecting a net loss of $0.16 per diluted share, %HeronTherapeutics (Nasdaq: HRTX) Q4 results came in at a net lo...
2024-03-13 13:18:36 ET More on Mid-day movers & stocks. Arq, Inc. (ARQ) Q4 2023 Earnings Call Transcript Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript Heron Therape...
2024-03-13 12:48:48 ET DENVER, Colo., Mar 13, 2024 ( 247marketnews.com )- Li-Cycle Holdings Corp. (NYSE: LICY ), Brera Holding ( NASDAQ:BREA ), Gaxos.ai Inc. (NASDAQ: GXAI ), The Beauty Health Company (NASDAQ: SKIN ), and Heron Therapeutics, Inc. (NASDAQ: HRTX ) are ...
2024-03-13 10:00:21 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-12 22:35:08 ET Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Conference Call March 12, 2024 4:30 PM ET Company Participants Craig Collard – Chief Executive Officer Kevin Warner – Senior Vice President-Medical Affairs Strategy and Engagement ...
2024-03-12 16:05:59 ET More on Heron Therapeutics Heron Therapeutics Is Out Of Survival Mode Upcoming FDA Decision: Heron Therapeutics' ZYNRELEF SNDA Heron Therapeutics Gets Back On Track Heron Therapeutics Q4 2023 Earnings Preview Heron Therapeutics ...
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates PR Newswire 2023 oncology care franchise revenue was $107.9 million , exceeding full-year 2023 guidance ZYNRELEF ® achieved quarterly...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...
2024-03-11 17:35:46 ET More on Heron Therapeutics Heron Therapeutics Is Out Of Survival Mode Upcoming FDA Decision: Heron Therapeutics' ZYNRELEF SNDA Heron Therapeutics Gets Back On Track Heron Therapeutics rises on securing label expansion for pain therapy ...
2024-03-11 17:35:46 ET Major earnings expected after the bell on Tuesday include: Clover Health Investments, Corp. ( CLOV ) SurgePays ( SURG ) Heron Therapeutics ( HRTX ) Qifu Technology ( QFIN ) Veritone ( VERI ) Read the full article on Se...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechn...